Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

* Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) * NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irr...